Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. (OTLK) Stock Ticker

NASDAQ: OTLK · Healthcare · Biotechnology
$0.6211-2.88%
USD · as of 2026-09-29 · market cap $116.1M
Open OTLK in TickrDownload for iPhone

OTLK right now

21% of the float is sold short.
Options expect by Oct 6±20.8%
Options expect by Oct 29±43.0%
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full OTLK picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on OTLK
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.

OTLK stock facts

Ticker symbolOTLK
ExchangeNASDAQ Capital Market
SectorHealthcare
IndustryBiotechnology
Market cap$116.1M
CEORobert Charles Jahr
Employees17
HeadquartersIselin, NJ, US
IPO date2016-06-14
Websitewww.outlooktherapeutics.com

What you can see for OTLK on Tickr

Live OTLK price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the OTLK report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for Outlook Therapeutics, Inc.?

The ticker symbol for Outlook Therapeutics, Inc. is OTLK, listed on the NASDAQ Capital Market.

What is OTLK?

Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated…

HomeExploreMarketLists
All pages